(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 11.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Karyopharm Therapeutics's revenue in 2023 is $145,866,000.On average, 7 Wall Street analysts forecast KPTI's revenue for 2023 to be $17,160,742,406, with the lowest KPTI revenue forecast at $16,792,973,760, and the highest KPTI revenue forecast at $17,414,893,332. On average, 7 Wall Street analysts forecast KPTI's revenue for 2024 to be $19,050,095,121, with the lowest KPTI revenue forecast at $15,036,022,338, and the highest KPTI revenue forecast at $23,199,088,945.
In 2025, KPTI is forecast to generate $23,422,659,295 in revenue, with the lowest revenue forecast at $16,610,864,715 and the highest revenue forecast at $28,707,944,844.